Immunogenicity, Safety, and Tolerability of 13-valent Pneumococcal Conjugate Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: an Open-label Study

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2015 Apr 15

PMID 25870329

Citations 28

Authors

Catherine Cordonnier

Per Ljungman

Christine Juergens

Johan Maertens

Dominik Selleslag

Vani Sundaraiyer

Peter C Giardina

Keri Clarke

William C Gruber

Daniel A Scott

Beate Schmoele-Thoma

Affiliations

Soon will be listed here.

Abstract

Background: Life-threatening Streptococcus pneumoniae infections often occur after hematopoietic stem cell transplant (HSCT); vaccination is important for prevention.

Methods: In an open-label study, patients (n = 251) 3-6 months after allogeneic HSCT received 3 doses of 13-valent pneumococcal conjugate vaccine (PCV13) at 1-month intervals, a fourth dose 6 months later, and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later. Immunogenicity at prespecified time points and vaccine safety were assessed.

Results: In the evaluable immunogenicity population (N = 216; mean age, 37.8 years), geometric mean fold rises (GMFRs) of immunoglobulin G geometric mean concentrations from baseline to postdose 3 showed significant increases in antibody levels across all PCV13 serotypes (GMFR range, 2.99-23.85; 95% confidence interval lower limit, >1); there were significant declines over the next 6 months, significant increases from predose 4 to postdose 4 (GMFR range, 3.00-6.97), and little change after PPSV23 (GMFR range, 0.86-1.12). Local and systemic reactions were more frequent after dose 4. Six patients experienced serious adverse events possibly related to PCV13 (facial diplegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack of vaccine efficacy after dose 3 leading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barré syndrome), or PPSV23 (cellulitis). There were 14 deaths, none related to study vaccines.

Conclusions: A 3-dose PCV13 regimen followed by a booster dose may be required to protect against pneumococcal disease in HSCT recipients. Dose 4 was associated with increased local and systemic reactions, but the overall safety profile of a 4-dose regimen was considered acceptable.

Clinical Trials Registration: NCT00980655.

Citing Articles

Vaccination After Haematopoietic Stem Cell Transplant: A Review of the Literature and Proposed Vaccination Protocol.

Silva-Pinto A, Abreu I, Martins A, Bastos J, Araujo J, Pinto R Vaccines (Basel). 2025; 12(12.

PMID: 39772108 PMC: 11680230. DOI: 10.3390/vaccines12121449.

Vaccination of Adults With Cancer: ASCO Guideline.

Kamboj M, Bohlke K, Baptiste D, Dunleavy K, Fueger A, Jones L J Clin Oncol. 2024; 42(14):1699-1721.

PMID: 38498792 PMC: 11095883. DOI: 10.1200/JCO.24.00032.

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.

Kobayashi M, Pilishvili T, Farrar J, Leidner A, Gierke R, Prasad N MMWR Recomm Rep. 2023; 72(3):1-39.

PMID: 37669242 PMC: 10495181. DOI: 10.15585/mmwr.rr7203a1.

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.

Reynolds G, Hall V, Teh B Transpl Infect Dis. 2023; 25 Suppl 1:e14109.

PMID: 37515788 PMC: 10909447. DOI: 10.1111/tid.14109.

A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).

Wilck M, Cornely O, Cordonnier C, Velez J, Ljungman P, Maertens J Clin Infect Dis. 2023; 77(8):1102-1110.

PMID: 37338158 PMC: 10573722. DOI: 10.1093/cid/ciad349.

References

Cordonnier C, Labopin M, Chesnel V, Ribaud P, de la Camara R, Martino R . Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009; 48(10):1392-401. DOI: 10.1086/598324. View

Bonten M, Huijts S, Bolkenbaas M, Webber C, Patterson S, Gault S . Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372(12):1114-25. DOI: 10.1056/NEJMoa1408544. View

Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J . Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10):1143-238. PMC: 3103296. DOI: 10.1016/j.bbmt.2009.06.019. View

Ljungman P, Cordonnier C, Einsele H, Englund J, Machado C, Storek J . Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 44(8):521-6. DOI: 10.1038/bmt.2009.263. View

Pilishvili T, Lexau C, Farley M, Hadler J, Harrison L, Bennett N . Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2009; 201(1):32-41. DOI: 10.1086/648593. View

Cordonnier C, Labopin M, Chesnel V, Ribaud P, de la Camara R, Martino R . Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine. 2010; 28(15):2730-4. DOI: 10.1016/j.vaccine.2010.01.025. View

Ljungman P, Small T . Update to vaccination guidelines. Biol Blood Marrow Transplant. 2010; 16(11):1608-9. DOI: 10.1016/j.bbmt.2010.08.009. View

Schwarz T, Flamaing J, Rumke H, Penzes J, Juergens C, Wenz A . A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011; 29(32):5195-202. DOI: 10.1016/j.vaccine.2011.05.031. View

Cooper D, Yu X, Sidhu M, Nahm M, Fernsten P, Jansen K . The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011; 29(41):7207-11. PMC: 3170457. DOI: 10.1016/j.vaccine.2011.06.056. View

10.

Miller E, Andrews N, Waight P, Slack M, George R . Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29(49):9127-31. DOI: 10.1016/j.vaccine.2011.09.112. View

11.

Clutterbuck E, Lazarus R, Yu L, Bowman J, Bateman E, Diggle L . Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012; 205(9):1408-16. PMC: 3324398. DOI: 10.1093/infdis/jis212. View

12.

Singleton R, Wenger J, Klejka J, Bulkow L, Thompson A, Sarkozy D . The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J. 2012; 32(3):257-63. DOI: 10.1097/INF.0b013e3182748ada. View

13.

Kaplan S, Barson W, Lin P, Romero J, Bradley J, Tan T . Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013; 32(3):203-7. DOI: 10.1097/INF.0b013e318275614b. View

14.

Jackson L, Gurtman A, van Cleeff M, Jansen K, Jayawardene D, Devlin C . Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013; 31(35):3577-84. DOI: 10.1016/j.vaccine.2013.04.085. View

15.

Torda A, Chong Q, Lee A, Chen S, Dodds A, Greenwood M . Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2014; 16(5):751-9. DOI: 10.1111/tid.12268. View

16.

Tomczyk S, Bennett N, Stoecker C, Gierke R, Moore M, Whitney C . Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014; 63(37):822-5. PMC: 5779453. View

17.

Vernacchio L, Romero-Steiner S, Martinez J, MacDonald K, Barnard S, Pilishvili T . Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis. 2000; 181(3):1162-6. DOI: 10.1086/315307. View

18.

Ada G . Vaccines and vaccination. N Engl J Med. 2001; 345(14):1042-53. DOI: 10.1056/NEJMra011223. View

19.

. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2001; 49(RR-10):1-125, CE1-7. View

20.

Engelhard D, Cordonnier C, Shaw P, Parkalli T, Guenther C, Martino R . Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002; 117(2):444-50. DOI: 10.1046/j.1365-2141.2002.03457.x. View